111 related articles for article (PubMed ID: 23724629)
1. Multiple resistance to betalactam antibiotics, azithromycin or moxifloxacin in implant associated bacteria.
Karbach J; Callaway AS; Willershausen B; Wagner W; Al-Nawas B
Clin Lab; 2013; 59(3-4):381-7. PubMed ID: 23724629
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic resistance testing of the total implant-associated micro-flora and its pure isolates.
Karbach J; Callaway A; Willershausen B; Wagner W; Geibel MA; Al-Nawas B
Eur J Med Res; 2007 Mar; 12(3):120-8. PubMed ID: 17507308
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Ngan CC; Lim T; Choo CM; Toh GL; Lim YS
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):207-10. PubMed ID: 15023431
[TBL] [Abstract][Full Text] [Related]
4. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
Carryn S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
Antimicrob Agents Chemother; 2002 Jul; 46(7):2095-103. PubMed ID: 12069960
[TBL] [Abstract][Full Text] [Related]
5. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
[TBL] [Abstract][Full Text] [Related]
6. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Mouratidou A; Karbach J; d'Hoedt B; Al-Nawas B
J Periodontol; 2011 Sep; 82(9):1360-6. PubMed ID: 21405933
[TBL] [Abstract][Full Text] [Related]
9. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
Tomás I; Tomás M; Alvarez M; Velasco D; Potel C; Limeres J; Diz P
Oral Microbiol Immunol; 2007 Oct; 22(5):298-303. PubMed ID: 17803626
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.
Tortoli E; Dionisio D; Fabbri C
J Chemother; 2004 Aug; 16(4):334-6. PubMed ID: 15332706
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Drago L; De Vecchi E; Nicola L; Legnani D; Prenna M; Ripa S
J Chemother; 2005 Apr; 17(2):161-8. PubMed ID: 15920900
[TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
19. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
